---
category: news
title: "Velan Capital Agrees to Support Merger of Lantheus and Progenics"
excerpt: "About Progenics Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find ... who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation ..."
publishedDateTime: 2020-04-14T13:00:00Z
webUrl: "https://www.businesswire.com/news/home/20200414005506/en/ADDING-MULTIMEDIA-Velan-Capital-Agrees-Support-Merger"
type: article
quality: 24
heat: -1
published: false

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mms.businesswire.com/media/20200414005506/en/479704/23/Lantheus%C2%AE_Holdings_RGB.jpg"
    width: 1200
    height: 627
    title: "Velan Capital Agrees to Support Merger of Lantheus and Progenics"

related:
  - title: "ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics"
    excerpt: "Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture"
    publishedDateTime: 2020-04-14T15:17:00Z
    webUrl: "https://www.marketwatch.com/press-release/adding-multimedia-velan-capital-agrees-to-support-merger-of-lantheus-and-progenics-2020-04-14"
    type: article
    provider:
      name: MarketWatch
      domain: marketwatch.com
    quality: 48
    images:
      - url: "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png"
        width: 1200
        height: 630

secured: "p0Lxl0bFBdq2B8Ijqgu1tkhMTeRVqs0QfPWJzLeJV6tOxK1gcRJmHLhQap7Y5VpRnSAkfV2d8f+lTUla5XHZa3CkL8iO4NruvPX99+kLdxeOgedeS3X9n5AzlsNb59mvJFoqT+Fg5UbTWc8xqW45L5JGyZDcmulm9m4OzeAMPULqB/foQPFthREHPob+aub2T2R75rhW+eTLtL12ELb3gOl+D7WYmjo3nLLyJUQiMofDVfyZPcickKEXNnSScEcCrUpCfA9Hlo5vgP1cQjJX2dX6lFSBp2KXqa9QnEgJ7f2QI2ieRjs30YNYmPpWJdFq;dlhAR60hLfdWO6Y0NvqJLQ=="
---

